Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Permax Cardiac Valvulopathy Safety Warning Added To Labeling

Executive Summary

Lilly is updating Permax labeling to include a warning on cardiac valvulopathy incidence associated with the Parkinson's disease treatment

You may also be interested in...



Permax Patients Should Be Evaluated For Somnolence, Lilly Says

Lilly is updating Permax (pergolide) labeling to include a warning that the Parkinson's drug may cause patients to fall asleep without warning

Permax Patients Should Be Evaluated For Somnolence, Lilly Says

Lilly is updating Permax (pergolide) labeling to include a warning that the Parkinson's drug may cause patients to fall asleep without warning

Amarin/Elan Parkinson's deal

Amarin plans to file an NDA for rapid-dissolving selegiline formulation Zelapar in the first half of 2002 following the acquisition from Elan of U.S. rights to the Parkinson's treatment. London-based Amarin (formerly Ethical Holdings) will also promote the Parkinson's therapy Permax (pergolide) with 24 reps; the product generated sales of $40 mil. in 2000

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel